Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study included 20 insulin-naïve type 2 diabetic patien...
Enregistré dans:
Auteurs principaux: | Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bb9f11fa3266492f955d458c1ee4ebc2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
par: Gagik Radikovich Galstyan
Publié: (2014) -
Insulin degludec is a new ultra-long-acting insulin analogue
par: Ivan Ivanovich Dedov, et autres
Publié: (2014) -
Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications
par: Vadim Valer'evich Klimontov, et autres
Publié: (2014) -
The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
par: M. V. Shestakova, et autres
Publié: (2021) -
Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
par: Marina Vladimirovna Shestakova, et autres
Publié: (2015)